EpimAb is a biopharmaceutical startup that operates in the oncology sector, developing innovative cancer treatments. The company has a robust and sustainable product pipeline, with four clinical projects and over ten pre-clinical candidate drugs. EpimAb's proprietary FIT-Ig® platform allows the company to precisely target three strategic oncology areas: tumor targeting, dual immune checkpoint, and immune cell guidance. This means they develop drugs that can target specific cancer cells, check the immune system's response, and guide immune cells to the tumor.

One of their key products, EMB-01, is a novel bispecific antibody, a type of drug that can bind to two different proteins at the same time. EMB-01 targets EGFR and cMet on tumor cells, which are proteins that can promote cancer growth. This drug is currently in Phase I/II clinical trials for non-small cell lung cancer (NSCLC) and several gastrointestinal (GI) cancers in the U.S. and China.

Another product, EMB-06, is a recombinant humanized bispecific antibody that targets B cell maturation antigen (BCMA) and cluster of differentiation 3 (CD3) on tumor cells. This drug can recruit and activate T lymphocytes, a type of white blood cell, to kill tumor cells. It is currently in a global Phase I/II study in Australia and China for multiple myeloma, a type of blood cancer.

EpimAb's business model revolves around the research, development, and commercialization of these innovative cancer treatments. The company makes money by progressing these drugs through clinical trials and eventually selling them to healthcare providers and patients.

Keywords: Biopharmaceutical, Oncology, Cancer Treatment, FIT-Ig® Platform, Bispecific Antibody, Tumor Targeting, Immune Checkpoint, Immune Cell Guidance, Clinical Trials, Drug Development.